Latest / Breaking News To Trading Moves
AbbVie’s $10.9 Billion Apogee Deal
AbbVie is buying Apogee Therapeutics in a $10.9 billion deal, giving AbbVie access to Apogee’s lead inflammatory disease drug candidate, zumilokibart. The drug is being studied for conditions including atopic dermatitis and asthma. This matters because immunology remains one of the most valuable areas in healthcare, and big pharma still needs new growth as patent cliffs and competition pressure older blockbuster drugs.
Winners
Direct deal beneficiaries
AbbVie is the strategic winner because the deal strengthens its immunology pipeline and adds another possible growth driver beyond Humira…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.